

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal653rbm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 4 OCT 03 MATHDI removed from STN
NEWS 5 OCT 04 CA/CAPLUS-Canadian Intellectual Property Office (CIPO) added
to core patent offices
NEWS 6 OCT 06 STN AnaVist workshops to be held in North America
NEWS 7 OCT 13 New CAS Information Use Policies Effective October 17, 2005
NEWS 8 OCT 17 STN(R) AnaVist(TM), Version 1.01, allows the export/download
of CAPLUS documents for use in third-party analysis and
visualization tools
NEWS 9 OCT 27 Free KWIC format extended in full-text databases
NEWS 10 OCT 27 DIOGENES content streamlined
NEWS 11 OCT 27 EPFULL enhanced with additional content
NEWS 12 NOV 14 CA/CAPLUS - Expanded coverage of German academic research

NEWS EXPRESS NOVEMBER 18 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:47:40 ON 21 NOV 2005

=> index bioscience

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,

AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS,
BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB,
CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 17:47:55 ON 21 NOV 2005

74 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=>

=> (alpha with facor with leader with sequence) and (ADH2 with promoter) and
("interleukin" with "2" with sequences)

13 FILES SEARCHED...
15 FILES SEARCHED...
21 FILES SEARCHED...
27 FILES SEARCHED...
34 FILES SEARCHED...
48 FILES SEARCHED...
54 FILES SEARCHED...
64 FILES SEARCHED...
72 FILES SEARCHED...

0 FILES HAVE ONE OR MORE ANSWERS, 74 FILES SEARCHED IN STNINDEX

L1 QUE (ALPHA WITH FACOR WITH LEADER WITH SEQUENCE) AND (ADH2 WITH PROMOTER)
AND ("INTERLEUKIN" WITH "2" WITH SEQUENCES)

=> alpha and facor and leader and sequence and and ADH2 with promoter and
("interleukin" with "2") and sequences

MISSING TERM 'AND AND'

The search profile that was entered contains a logical
operator followed immediately by another operator.

=> (ADH2 with promoter) and ("interleukin" with "2" with sequences)

15 FILES SEARCHED...
27 FILES SEARCHED...
34 FILES SEARCHED...
39 FILES SEARCHED...
54 FILES SEARCHED...
66 FILES SEARCHED...

0 FILES HAVE ONE OR MORE ANSWERS, 74 FILES SEARCHED IN STNINDEX

L2 QUE (ADH2 WITH PROMOTER) AND ("INTERLEUKIN" WITH "2" WITH SEQUENCES)

=> (alpha with facor with leader with sequence) and (ADH2 with promoter)

15 FILES SEARCHED...
27 FILES SEARCHED...
34 FILES SEARCHED...
47 FILES SEARCHED...
54 FILES SEARCHED...
68 FILES SEARCHED...

0 FILES HAVE ONE OR MORE ANSWERS, 74 FILES SEARCHED IN STNINDEX

L3 QUE (ALPHA WITH FACOR WITH LEADER WITH SEQUENCE) AND (ADH2 WITH PROMOTER)

=> (alpha with facor with leader with sequence)

15 FILES SEARCHED...
25 FILES SEARCHED...
27 FILES SEARCHED...
36 FILES SEARCHED...
54 FILES SEARCHED...
71 FILES SEARCHED...

0 FILES HAVE ONE OR MORE ANSWERS, 74 FILES SEARCHED IN STNINDEX

L4 QUE (ALPHA WITH FACOR WITH LEADER WITH SEQUENCE)

=> (alpha with factor with leader with sequence)

```
3 FILE AGRICOLA
7 FILE BIOBUSINESS
30 FILE BIOSIS
34 FILE BIOTECHABS
34 FILE BIOTECHDS
15 FILES SEARCHED...
1 FILE CABA
5 FILE CANCERLIT
66 FILE CAPLUS
85 FILE DGENE
27 FILES SEARCHED...
1 FILE DISSABS
1 FILE DRUGU
34 FILES SEARCHED...
2 FILE GENBANK
40 FILES SEARCHED...
24 FILE IFIPAT
16 FILE LIFESCI
23 FILE MEDLINE
54 FILES SEARCHED...
3 FILE PROMT
14 FILE TOXCENTER
543 FILE USPATFULL
43 FILE USPAT2
71 FILES SEARCHED...
12 FILE WPIDS
12 FILE WPINDEX
```

21 FILES HAVE ONE OR MORE ANSWERS, 74 FILES SEARCHED IN STNINDEX

L5 QUE (ALPHA WITH FACTOR WITH LEADER WITH SEQUENCE)

=> (alpha with factor with leader with sequence) and (ADH2 with promoter)

```
1 FILE BIOSIS
4 FILE BIOTECHABS
4 FILE BIOTECHDS
15 FILES SEARCHED...
1 FILE CABA
6 FILE CAPLUS
26 FILES SEARCHED...
3 FILE DGENE
27 FILES SEARCHED...
34 FILES SEARCHED...
46 FILES SEARCHED...
1 FILE MEDLINE
54 FILES SEARCHED...
1 FILE TOXCENTER
399 FILE USPATFULL
36 FILE USPAT2
68 FILES SEARCHED...
1 FILE WPIDS
1 FILE WPINDEX
```

12 FILES HAVE ONE OR MORE ANSWERS, 74 FILES SEARCHED IN STNINDEX

L6 QUE (ALPHA WITH FACTOR WITH LEADER WITH SEQUENCE) AND (ADH2 WITH PROMOTER)

```
=> (alpha with factor with leader with sequence) and (ADH2 with promoter) and IL2
14 FILES SEARCHED...
18 FILES SEARCHED...
27 FILES SEARCHED...
34 FILES SEARCHED...
51 FILES SEARCHED...
54 FILES SEARCHED...
      8 FILE USPATFULL
      1 FILE USPAT2
68 FILES SEARCHED...
```

2 FILES HAVE ONE OR MORE ANSWERS, 74 FILES SEARCHED IN STNINDEX

L7 QUE (ALPHA WITH FACTOR WITH LEADER WITH SEQUENCE) AND (ADH2 WITH PROMOTER)
AND IL2

=> d rank

```
F1      8 USPATFULL
F2      1 USPAT2
```

=> (alpha with factor with leader with sequence) and (ADH2 with promoter)

```
      1 FILE BIOSIS
      4 FILE BIOTECHABS
      4 FILE BIOTECHDS
15 FILES SEARCHED...
      1 FILE CABA
      6 FILE CAPLUS
25 FILES SEARCHED...
      3 FILE DGENE
27 FILES SEARCHED...
34 FILES SEARCHED...
      1 FILE MEDLINE
51 FILES SEARCHED...
54 FILES SEARCHED...
      1 FILE TOXCENTER
    399 FILE USPATFULL
67 FILES SEARCHED...
     36 FILE USPAT2
      1 FILE WPIDS
      1 FILE WPINDEX
```

12 FILES HAVE ONE OR MORE ANSWERS, 74 FILES SEARCHED IN STNINDEX

L8 QUE (ALPHA WITH FACTOR WITH LEADER WITH SEQUENCE) AND (ADH2 WITH PROMOTER)

=> d rank

```
F1    399 USPATFULL
F2     36 USPAT2
F3      6 CAPLUS
F4      4 BIOTECHABS
F5      4 BIOTECHDS
F6      3 DGENE
F7      1 BIOSIS
F8      1 CABA
F9      1 MEDLINE
F10     1 TOXCENTER
F11     1 WPIDS
F12     1 WPINDEX
```

=> file caplus biotechabs biosis
COST IN U.S. DOLLARS

SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	67.85	68.06

FILE 'CAPLUS' ENTERED AT 18:56:44 ON 21 NOV 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOSIS' ENTERED AT 18:56:44 ON 21 NOV 2005
 Copyright (c) 2005 The Thomson Corporation

=> file caplus biotechabs biosis		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	1.30	69.36

FILE 'CAPLUS' ENTERED AT 18:56:47 ON 21 NOV 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOTECHABS' TEMPORARILY UNAVAILABLE

FILE 'BIOSIS' ENTERED AT 18:56:47 ON 21 NOV 2005
 Copyright (c) 2005 The Thomson Corporation
 If this message appears repeatedly, please notify the Help Desk.
 Enter "HELP STN" for information on contacting the nearest STN Help
 Desk by telephone or via SEND in the STNMAIL file.

=> (alpha with factor with leader with sequence) and (ADH2 with promoter)
 L9 7 (ALPHA WITH FACTOR WITH LEADER WITH SEQUENCE) AND (ADH2 WITH
 PROMOTER)

=> d ab bib 1-7

L9 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
 AB Provided is a method for producing physiol. active protein in high yields
 by controlling the redox potential of a fermentation A physiol. active protein
 such as IFN- α is characteristically produced in a high yield by
 using Saccharomyces cerevisiae DCO4 (KCTC0051BP) which is transformed with
 a plasmid having **ADH2/GAP promoter, alpha-**
factor leader sequence, and genes of
 IFN-alpha, adjusting pH within the range of 4 to 8 for the fermentation and
 metal ions as oxidants or sulfur compound as reductants to keep redox
 potential value to be greater than 0 and smaller than 180.
 AN 2004:856530 CAPLUS
 DN 142:133164
 TI Fermentation process for producing active proteins from recombinant
 Saccharomyces cerevisiae using redox potential control
 IN Kwon, In Chan; Han, Kyu Boem
 PA Lg Chemical Co., Ltd, S. Korea
 SO Repub. Korea, No pp. given
 CODEN: KRXXFC
 DT Patent
 LA Korean
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	KR 235462	B1	19991215	KR 1997-9188	19970318
PRAI	KR 1997-9188		19970318		

L9 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AB A method for controlling oxidation and reduction of physiol. active protein, which is produced from fermentation of recombinant microorganism, is provided by

adding oxidant and reductant. Physiol. active protein, for example, IFN- α is produced in a high yield by using *Saccharomyces cerevisiae* DCO4(KCTC 0051BP), which is transformed with a plasmid having **ADH2/GAP promoter, alpha-factor leader sequence** and genes of IFN-alpha, and adding 1-50 mM of sulfur compound as a reductant into medium wherein, the sulfur compound is selected from DTT(dithiothreitol), cysteine, or β -mercaptoethanol.

AN 2004:856529 CAPLUS

DN 142:133163

TI Redox potential control during *Saccharomyces cerevisiae* recombinant protein fermentations

IN Kwon, In Chan; Han, Kyu Boem

PA Lg Chemical Co., Ltd, S. Korea

SO Repub. Korea, No pp. given

CODEN: KRXXFC

DT Patent

LA Korean

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	KR 235461	B1	19991215	KR 1996-39670	19960913
PRAI	KR 1996-39670		19960913		

L9 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AB A method for mass producing human interferon alpha(IFN- α) from the recombinant yeast is provided to improve a production yield and facilitate folding of the IFN- α . Human IFN α is mass produced from the recombinant yeast by incubating *Saccharomyces cerevisiae* DC04 transformed by the plasmid containing **ADH2/GAP promoter, alpha-factor leader sequence**, and the IFN-alpha gene in a medium containing metal ion at 25 to 30°, pH 4.5 to 5.0 under aerobic condition, adding a proper amount of glucose (avoiding accumulation in the medium), at the time of starting expression by exhaustion of glucose and ethanol. A 0.1 to 10 mM of metal ion is added into the medium to facilitate folding of the IFN- α ; it contains copper, iron, zinc, manganese, molybdenum, and cobalt.

AN 2004:852101 CAPLUS

DN 142:79847

TI Method for mass producing human interferon alpha(IFN- α) from recombinant yeast

IN Han, Gyu Beom; Kwon, Seon Hun

PA Lg Chemical Co., Ltd., S. Korea

SO Repub. Korea, No pp. given

CODEN: KRXXFC

DT Patent

LA Korean

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	KR 177321	B1	19990401	KR 1996-26844	19960703
PRAI	KR 1996-26844		19960703		

L9 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AB A method for producing human granulocyte colony stimulation factor(G-CSF) from recombinant yeast is provided. Recombinant yeast *Saccharomyces cerevisiae* DCO4, which is transformed by a plasmid containing alc. dehydrogenase 2/glyceraldehyde-3-phosphate(**ADH2/GAP promoter, .alpha.-factor leader sequence**), and the G-CSF gene in which 17th cysteine from 5' terminal is substituted with serine, is fed-batch fermented under conditions of 25 to 30 °C and pH 4.5-5.0 glucose is added into

reactor in order to maintain the yeast growth rate to 0.08 to 0.12 /h when ethanol the concentration is zero.

AN 2004:844141 CAPLUS

DN 142:54843

TI Human granulocyte-colony stimulating factor expression in recombinant *Saccharomyces cerevisiae*

IN Han, Kyu Sum; Kwon, Sun Hoon; Lee, Heung Yeup

PA Lg Chemical Ltd, S. Korea

SO Repub. Korea, No pp. given

CODEN: KRXXFC

DT Patent

LA Korean

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	KR 154965	B1	19981015	KR 1996-75	19960105
PRAI	KR 1996-75		19960105		

L9 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AB Transmission-blocking vaccines based on sexual-stage surface antigens of *P. falciparum* may assist in the control of this lethal form of human malaria. Two vaccine candidates, Pfs25 and Pfs28, were produced as single recombinant fusion proteins. The 39-kDa chimeric proteins, having a C-terminal His6 tag, were secreted by *S. cerevisiae*, using the prepro-**alpha**-factor leader sequence.

Pfs25-28 fusion proteins were more potent than either Pfs25 or Pfs28 alone in eliciting antibodies in mice that blocked oocyst development in *Anopheles freeborni* mosquitoes: complete inhibition of oocyst development in the mosquito midgut was achieved with fewer vaccinations, at a lower dose, and for a longer duration than with either Pfs25 or Pfs28 alone. Increased antigen-specific IgG titers and highly significant lymphoproliferative stimulation by Pfs28-containing antigens suggest the presence of an immunodominant helper T-cell epitope in the Pfs28 portion of the fusion proteins. This epitope may be responsible for the enhanced humoral response to both Pfs25 and Pfs28 antigens. Protein production of the fusion protein was improved 12-fold by converting Pfs28 codons to yeast-preferred codons (TBV28), using a modified **ADH2 promoter** and incorporating a (Glu-Ala)₂ repeat after the Kex2 cleavage site.

AN 1998:7805 CAPLUS

DN 128:113774

TI *Saccharomyces cerevisiae*-secreted fusion proteins Pfs25 and Pfs28 elicit potent *Plasmodium falciparum* transmission-blocking antibodies in mice

AU Gozar, Mary Margaret G.; Price, Virginia L.; Kaslow, David C.

CS Malaria Vaccines Section, Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, MD, 20892-0425, USA

SO Infection and Immunity (1998), 66(1), 59-64

CODEN: INFIBR; ISSN: 0019-9567

PB American Society for Microbiology

DT Journal

LA English

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AB This article describes the construction of various alc. dehydrogenase 2 gene (**ADH2**) promoter plasmids for expression of heterologous proteins in yeast as well as for secretion into the culture medium. Plasmids YEpC-pADH2a, b, and d contain a polylinker following the **ADH2 promoter**. YEpC-PADH2a and YEpC-PADH2b contain the pUC13 polylinker in both orientations with unique restriction sites for SmaI, BamHI, and SalI. They do not have an ATG codon as does YEpC-PADH2d and therefore can be used for cloning and expression of intact genes. The yeast-*Escherichia coli* shuttle vector p α ADH2 allows regulated

secretion of heterologous proteins via the **ADH2 promoter** fused to the **.alpha.-factor leader sequence**. The YIp5-derived integrating vectors pBC36 and pBC72 allow overprodn. of ADR1 which is required for pos. activation of the **ADH2 promoter**. The expression of several cDNAs encoding mouse and human granulocyte-macrophage colony-stimulating factor and human and bovine interleukin II was tested using vector p α ADH2. The amount of heterologous protein secreted ranged from 5 to 70 μ g/mL.

AN 1990:546651 CAPLUS

DN 113:146651

TI Expression of heterologous proteins in *Saccharomyces cerevisiae* using the **ADH2 promoter**

AU Price, Virginia L.; Taylor, Wayne E.; Clevenger, William; Worthington, Marlis; Young, Elton T.

CS Dep. Mol. Biol., Immunex Corp., Seattle, WA, 98101, USA

SO Methods in Enzymology (1990), 185(Gene Expression Technol.), 308-18
CODEN: MENZAU; ISSN: 0076-6879

DT Journal

LA English

L9 ANSWER 7 OF 7 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

AB Transmission-blocking vaccines based on sexual-stage surface antigens of *Plasmodium falciparum* may assist in the control of this lethal form of human malaria. Two vaccine candidates, Pfs25 and Pfs28, were produced as single recombinant fusion proteins. The 39-kDa chimeric proteins, having a C-terminal His6 tag, were secreted by *Saccharomyces cerevisiae*, using the **prepro-alpha-factor leader sequence**.

Pfs25-28 fusion proteins were significantly more potent than either Pfs25 or Pfs28 alone in eliciting antibodies in mice that blocked oocyst development in *Anopheles freeborni* mosquitoes: complete inhibition of oocyst development in the mosquito midgut was achieved with fewer vaccinations, at a lower dose, and for a longer duration than with either Pfs25 or Pfs28 alone. Increased antigen-specific immunoglobulin G titers and highly significant lymphoproliferative stimulation by Pfs28-containing antigens suggest the presence of an immunodominant helper T-cell epitope in the Pfs28 portion of the fusion proteins. This epitope may be responsible for the enhanced humoral response to both Pfs25 and Pfs28 antigens. Protein production of the fusion protein was improved 12-fold by converting Pfs28 codons to yeast-preferred codons (TBV28), using a modified **ADH2 promoter** and incorporating a (Glu-Ala)₂ repeat after the Kex2 cleavage site.

AN 1998:78406 BIOSIS

DN PREV199800078406

TI *Saccharomyces cerevisiae*-secreted fusion proteins Pfs25 and Pfs28 elicit potent *Plasmodium falciparum* transmission-blocking antibodies in mice.

AU Gozar, Mary Margaret G.; Price, Virginia L.; Kaslow, David C. [Reprint author]

CS Malaria Vaccines Section, Lab. Parasitic Diseases, Natl. Inst. Health, Build. 4, Room B1-31, Bethesda, MD 20892-0425, USA

SO Infection and Immunity, (Jan., 1998) Vol. 66, No. 1, pp. 59-64. print.
CODEN: INFIBR. ISSN: 0019-9567.

DT Article

LA English

ED Entered STN: 24 Feb 1998

Last Updated on STN: 24 Feb 1998